

**Remarks**

Claims 1-24 have been canceled without prejudice or disclaimer. Applicants reserve the right to pursue subject matter encompassed by all canceled claims in one or more divisional or continuation applications. Claims 25-48 have been added to expand the embodiments of the elected subject matter. No new matter has been added.

Claims 25-48 are supported by the specification and claims as originally filed. For example, support for claims 25-48 can be found in the specification at: page 37, paragraph [0099] to page 40, paragraph [0106]; page 86, Table I, rows 9 & 10; page 89, paragraph [0226] to page 94, paragraph [0249]; page 96, paragraph [0245] to page 104, paragraph [0281]. No new matter has been added.

**Restriction Requirement/Election**

A restriction requirement has been issued in which claims 1-24 were separated into 310 different groups. See, Paper No. 26052005, pages 2-6.

To comply with the pending restriction requirement, Applicants herein elect claims embodying the subject matter restricted to Group 44 (*i.e.*, polypeptides encoded by Gene No. 13, cDNA Clone ID HCNT-61, and represented by amino acid SEQ ID NO:60 and SEQ ID NO:83 (*See*, Specification, Table I, page 86, rows 9 & 10)). New claims 25-48 have been added to more fully expand the embodiments of the elected subject matter. The subject matter encompassed by these claims fall within the ambit of Group 44 as cast by the Examiner. See, Paper No. 26052005, pages 3-4, item II.

**Request To Amend Inventorship Pursuant to 37 C.F.R. §1.48(b)**

Applicants respectfully request amendment of inventorship pursuant to 37 C.F.R. §1.48(b) (*Non-provisional application - fewer inventors due to amendment or cancellation of claims*). Applicants submit concurrently herewith a Fee Transmittal (in duplicate), authorizing payment of the processing fee under 37 C.F.R. § 1.17(i).

The claims in the present application have been amended such that the inventive entity of the currently claimed subject matter does not include the following persons:

DUAN, D. Roxanne  
YANG, Shi  
LaFLEUR, David W.  
YOUNG, Paul E.

KOMARIS, George A.  
ENDRISS, Gregory A.  
SOPP, Daniel R.

Accordingly, Applicants hereby request that the above-named inventors be deleted from the present application:

Conversely, the undersigned has been informed that the inventive entity of the subject matter encompassed by the currently pending claims are those names shown below. Accordingly, Applicants request that the present application be amended to show only the three persons named below as inventors.

RUBEN, Steven M.  
ROSE, Craig A.  
NI, Ji

Conclusion


Applicants respectfully request that the amendments and remarks submitted herein be entered in the present application. The Examiner is invited to call the undersigned at the phone number provided below if any further action by Applicants would expedite the examination of this application.

If there are any fees not already accounted for due in connection with the filing of this paper, please charge the fees to our Deposit Account No. 08-3425. If a fee is required for an extension of time under C.F.R. § 1.136, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

Date:

July 6, 2005

  
Doyle A. Siever (Reg. No. 47,088)  
Agent for Applicants

Human Genome Sciences, Inc.  
Intellectual Property Department  
14200 Shady Grove Road  
Rockville, MD 20850  
(301) 354-3932 (phone)

KKH/DAS/mr